QUINCE THERAPEUTICS INC (QNCX)

US22053A1079 - Common Stock

2.41  +0.33 (+15.87%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to QNCX. QNCX was compared to 565 industry peers in the Biotechnology industry. The financial health of QNCX is average, but there are quite some concerns on its profitability. QNCX is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year QNCX has reported negative net income.
In the past year QNCX has reported a negative cash flow from operations.
In the past 5 years QNCX always reported negative net income.
QNCX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -42.10%, QNCX is in line with its industry, outperforming 55.62% of the companies in the same industry.
QNCX has a Return On Equity (-118.54%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.1%
ROE -118.54%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-41.24%
ROE(3y)-54.69%
ROE(5y)-48.14%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

QNCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, QNCX has more shares outstanding
Compared to 5 years ago, QNCX has more shares outstanding
Compared to 1 year ago, QNCX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.91, we must say that QNCX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of QNCX (-3.91) is comparable to the rest of the industry.
QNCX has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
QNCX has a Debt to Equity ratio of 0.33. This is in the lower half of the industry: QNCX underperforms 71.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -3.91
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 9.53 indicates that QNCX has no problem at all paying its short term obligations.
QNCX has a Current ratio of 9.53. This is amongst the best in the industry. QNCX outperforms 80.39% of its industry peers.
QNCX has a Quick Ratio of 9.53. This indicates that QNCX is financially healthy and has no problem in meeting its short term obligations.
QNCX has a Quick ratio of 9.53. This is amongst the best in the industry. QNCX outperforms 80.57% of its industry peers.
Industry RankSector Rank
Current Ratio 9.53
Quick Ratio 9.53

More info and screens

1

3. Growth

3.1 Past

The earnings per share for QNCX have decreased strongly by -59.76% in the last year.
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

QNCX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.13%
EPS Next 2Y37.73%
EPS Next 3Y25.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QNCX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as QNCX's earnings are expected to grow with 25.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.73%
EPS Next 3Y25.01%

More info and screens

0

5. Dividend

5.1 Amount

QNCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUINCE THERAPEUTICS INC

NASDAQ:QNCX (11/22/2024, 1:25:01 PM)

2.41

+0.33 (+15.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap106.04M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.1%
ROE -118.54%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 9.53
Quick Ratio 9.53
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y62.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y